Status:

COMPLETED

Study Of Single And Multiple Ascending Doses Of PF-07054894 In Healthy Adult Participants

Lead Sponsor:

Pfizer

Conditions:

Healthy

Eligibility:

All Genders

18-55 years

Phase:

PHASE1

Brief Summary

The purpose of the study is to evaluate the safety, tolerability, and PK of single escalating doses and multiple escalating doses of PF-07054894.

Eligibility Criteria

Inclusion

  • Male and female (of non-child bearing potential) participants must be 18 to 55 years of age, inclusive, and with BMI of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb).
  • Male and female of non-child bearing potential participants who are overtly healthy as determined by medical evaluation.
  • Participants must be willing to avoid direct sunlight exposure or any high intensity ultraviolet light exposure, from admission to FU1 and to apply sun screen/lotion with a high sun protection factor, as appropriate.

Exclusion

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, immunological/rheumatological, or allergic diseases.
  • Evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB), history of HIV infection, hepatitis B, or hepatitis C.
  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Have a history of systemic infection requiring hospitalization, parenteral antimicrobial therapy, or as otherwise judged clinically significant by the investigator within 6 months prior to Day 1.
  • History of phototoxicity and photosensitivity.

Key Trial Info

Start Date :

July 27 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 21 2022

Estimated Enrollment :

84 Patients enrolled

Trial Details

Trial ID

NCT04388878

Start Date

July 27 2020

End Date

June 21 2022

Last Update

July 12 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Brussels Clinical Research Unit

Brussels, Bruxelles-capitale, Région de, Belgium, B-1070